The BIomarker Guided Study for Depression
Purpose
The diagnosis of major depression relies on patient reports, and two patients with the same diagnosis might share only one symptom. Thus, a single mechanism is unlikely to underlie a broad descriptive diagnosis such as major depression. Our approach is anchored by a neural circuit taxonomy that proposes distinct biotypes of depression derived from functional magnetic resonance imaging (fMRI) (Williams et al., 2016). In this study, we aim to target a putative type of major depression that arises from dysfunction in cognitive control neural circuitry with a drug called guanfacine.
Condition
- Major Depressive Disorder
Eligibility
- Eligible Ages
- Between 18 Years and 65 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- 18-65 years of age (inclusive) - DLPFC activity in the upper or lower quartile as compared to a normative sample - Working memory performance <= 1 SD below the mean of a normative sample on the Verbal Memory, Digit Span, or Maze tasks. - Score > 14 on the Hamilton Depression Rating Scale 17 - Meet DSM-5 diagnostic criteria for current, past, or recurrent nonpsychotic major depressive disorder established by MINI Plus - Medication naïve to guanfacine - Fluent and literate in English, and show non-impaired intellectual abilities to ensure adequate comprehension of the task instructions - Written, informed consent - fMRI scanning eligibility, including no evidence of any form of metal embedded in the body (e.g., metal wires, nuts, bolts, screws, plates, sutures), as these produce artifacts when brain imaging. All potential subjects will need to successfully complete the screening forms at the Stanford Center for Cognitive and Neurobiological Imaging (CNI).
Exclusion Criteria
- Presence of suicidal ideation representing imminent risk, defined by a score of > 8 on the MINI Plus International Neuropsychiatric Schedule, or by clinician judgement - Lifetime history of medical illness or injury that may compromise cognitive functioning or interfere with assessments (including neurological disorders such as seizures or stroke, Parkinson's disease, dementia, mild traumatic brain injury) - Severe impediment to vision, hearing and/or hand movement, likely to interfere with ability to complete the assessments, or are unable and/or unlikely to follow the study protocols - Pregnant, breastfeeding or unwilling or unable to use adequate birth control throughout the study - Any contraindication to being scanned in the 3.0T scanner at the CNI such as having a pacemaker or implanted device that has not been cleared for scanning at 3.0 Tesla - History of DSM-5 bipolar disorder (I, II, not otherwise specified), eating disorder, ADHD, schizophrenia, schizoaffective disorder, or psychosis not other specified (current or lifetime) - History of DSM-5 alcohol or substance use disorder criteria within the last 12 months - Meeting criteria for current DSM-5 PTSD or OCD - Concurrent participation in other intervention or treatment studies - Current use of psychotropic medications. If their usual treating physician is supportive, participants who are currently on psychotropics that can be safely tapered may be tapered off to participate but participant must wait 5 half-lives of the prescribed drug prior to first scan. - General medical condition, disease or neurological disorder that is deemed by the study physicians to be unsafe for GIR treatment (kidney or liver impairment, hypotension, bradycardia, history of syncope, or family history of cardiac events) - Positive drug screen for any substance deemed by the study physician to be unsafe for use with GIR in combination with other information obtained during screening - Current use of a strong CYP3A4 inhibitor or inducer
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- We will randomize participants to one of two groups, treatment or placebo. Participants will have the option to proceed to an open label phase, post-treatment.
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
- Masking Description
- Participants, Care Providers, and Investigators will be blinded throughout the course of the study to avoid bias.
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Guanfacine Treatment Group |
Participants will be prescribed tabs containing guanfacine immediate release (GIR) to be taken for 4 weeks and will be monitored by one of the study psychiatrists. Subjects randomized to GIR will start with 0.25mg GIR upon waking and increase by 0.25mg every other day with a goal dose of 2mg. |
|
|
Placebo Comparator Placebo Group |
Participants will be prescribed tabs containing placebo to be taken for 4 weeks and will be monitored by one of thestudy psychiatrists. Subjects randomized placebo will be asked to follow the same pill regimen as subjects randomized to treatment. |
|
Recruiting Locations
More Details
- Status
- Recruiting
- Sponsor
- Stanford University
Detailed Description
The flow of procedures and study visits is as follows: 1. Recruitment and screening: Participants experiencing depressive symptoms and not taking any psychiatric medications as determined by a 5 half life wash out period will be recruited from the community, including students and employees at Stanford. Recruitment will come primarily from Facebook ads, which will use only IRB approved material. The flyer will also be physically posted on boards in public locations in order to include a variety of sources for the study. 2. Individuals will need to participate in 2 to 3 screening visits (screening visit 2 and 3 can be combined) in order to enroll in the study. During the first visit, participants will go over informed consent, be administered a clinical interview and complete cognitive testing. 3. The second visit will be a medical screen in order to ensure participants are safe to continue and will include blood samples, medical history, vitals and a urine drug test and can be combined with visit three, detailed in step 4 below. 4. If the participant meets medical and cognitive criteria, scans for functional MRI will be undertaken at another study visit (or in combination with the medical screen) at the CNI on the Stanford campus. All MRI scans, including the optional MRI scan at week 6, will last 1.5 hours. If a participant's task-evoked activity in the DLPFC falls within the highest or lowest quartiles derived from a large data set of healthy volunteers, the participant will be able to proceed with medication 5. Participants will be randomized to either receive active medication treatment with guanfacine or placebo in a double blinded fashion. Randomization will be generated using a random number generator computer program. The probability for random assignment to each treatment is 50% chance randomized to active treatment with guanfacine and 50% chance randomized to placebo. A prescription lasting a period of 4 weeks will be sent to the Stanford Psychiatry Department from Mariner pharmacy. The pharmacist will provide a research coordinator in the lab with the randomization information, but this research coordinator will not be involved in patient interaction. The packaging of the medication itself will not identify drug or otherwise, but have an ID only. 6. At weeks 1, 3 and 5 when subject is not seen by the study MD, the participant will be monitored by an appropriately trained clinical research coordinator. All subjects will have an fMRI scan during week 4 and an optional week 6 fMRI scan. During in-person visits and phone monitoring, participants will be assessed for changes to physical health and treatment physical side-effects, anthropometrics and vital signs, changes to current medications (other than GIR), compliance to GIR treatment, alcohol and drug use abstinence compliance, birth control usage compliance and likelihood of pregnancy (female participants of child bearing potential), mood changes (QIDS-SR), suicidality (C-SSRS), clinical global impression severity (CGI-S) and improvement (CGI-I), Barratt Impulsiveness Scale (BIS). We will also have participants complete the following cognitive measures described below on a weekly basis during the treatment period in the form of an online battery (aka Webneuro): Choice reaction time, emotion test, digit span, GoNoGo, Verbal Interference, CPT, and Maze. DETAILS 1. Participants: Volunteers will be aged 18-65 years old. The effect size of guanfacine vs. placebo on ADHD symptoms, including symptoms of inattention, has been estimated to be between 0.43 and 0.86. Using the most conservative of these values (0.43) and assuming an alpha of 0.05 with 4 groups, a total of 64 patients will be needed to provide a power of 80%. This would result in 32 subjects in each of the highest and lowest quartile groups of DLPFC activity. 2. Randomization: Participants will undergo fMRI scanning using tasks described below, including the N-back Working Memory Task. A region of interest (ROI) analysis will be performed using our established methods, to identify BOLD- dependent signal change in the DPLPC (right, left). Beta values for each ROI will be extracted for each subject and used to determine eligibility for the study. If a subject falls with the extreme quartiles of either the right or left DLPFC or both, this individual be randomized in a double blind fashion into one of two groups: placebo or guanfacine. 3. Suicidal thoughts or psychotic symptoms: Established procedures are in place for direct and immediate referral and intervention when suicidality and/or psychosis are identified. 4. Participants wishing to participate in this study will be screened with a psychiatric interview, an in-person physical exam (height, weight, vital signs, systems assessment, general appearance), medical history (history of disorders, diseases and allergies), lab tests (hematology: hemoglobin, hematocrit, total and differential WBC count, platelet count; chemistry: sodium, potassium, chloride, CO2, glucose, creatinine, BUN/urea; liver panel: albumin, total bilirubin, direct bilirubin, AST, ALT, ALP, total protein; endocrine: TSH; pregnancy test; full urine toxicology). 5. Participants will be prescribed tabs containing either placebo or guanfacine immediate release to be taken for 4 weeks and will be monitored by one of the study psychiatrists. Subjects randomized to GIR will start with 0.25mg GIR upon waking and increase by 0.25mg every other day with a goal dose of 2mg. If intolerance is encountered with a dosage increase, the dosage will be reduced to the prior level for a length to be determined by the treating psychiatrist and then raised again if/when tolerated. Dosing schedule may be slowed at the discretion of the physician based on participant's reaction to the drug. Decision to terminate guanfacine treatment will be made by clinicians based on side effects or lack of response or at patient's request. Follow up care for 2 weeks will be provided and transfer of care arranged at week 6 according to patients' decisions. At 4 weeks, the blind will be broken and those taking GIR may choose to continue this medication or taper off. If patients select to continue, a fMRI scan will be offered at week 6. Abrupt discontinuation of GIR (either due to side effects or to study end) will be avoided to prevent rebound hypertension and withdrawal symptoms. Participants will be seen by the study's psychiatrists at treatment weeks 2, 4, and 6.
